Adenovirus E4-ORF3 targets PIAS3 and together with E1B-55K remodels SUMO interactions in the nucleus and at virus genome replication domains

Journal of Virology

Volumn 89, Issue 20, 2015, Pages 10260-10272

  Higginbotham, Jennifer M ^a   O'Shea, Clodagh C ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; E1B 55K PROTEIN; MRE11 PROTEIN; NIBRIN; PROTEIN E4 ORF3; PROTEIN PIAS1; PROTEIN PIAS2; PROTEIN PIAS3; PROTEIN PIAS4; RAD50 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VIRUS PROTEIN; ATM PROTEIN, HUMAN; CHAPERONE; E1B PROTEIN; PIAS3 PROTEIN, HUMAN; PROTEIN INHIBITOR OF ACTIVATED STAT; SUMO PROTEIN; SUMO2 PROTEIN, HUMAN; SUMO3 PROTEIN, HUMAN; UBIQUITIN; VIRAL PROTEIN;

ARTICLE; BINDING AFFINITY; CELL COMPARTMENTALIZATION; CELL NUCLEUS; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; STRUCTURE ANALYSIS; SUMOYLATION; VIRUS GENOME; VIRUS REPLICATION; WILD TYPE; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; GENE EXPRESSION REGULATION; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; HUMAN ADENOVIRUS C; METABOLISM; MOLECULAR GENETICS; OPEN READING FRAME; OSTEOBLAST; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VIROLOGY;

ADENOVIRUS E1B PROTEINS; ADENOVIRUS E4 PROTEINS; ADENOVIRUSES, HUMAN; AMINO ACID SEQUENCE; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS; GENE EXPRESSION REGULATION; GENOME, VIRAL; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, MOLECULAR; MOLECULAR CHAPERONES; MOLECULAR SEQUENCE DATA; OPEN READING FRAMES; OSTEOBLASTS; PROTEIN INHIBITORS OF ACTIVATED STAT; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SUMOYLATION; UBIQUITINS; VIRUS REPLICATION;

EID: 84942162738     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01091-15     Document Type: Article

References (65)

1. Witte ON, Dasgupta A, Baltimore D. 1980. Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine. Nature 283:826-831. http://dx.doi.org/10.1038/283826a0.
2. Hunter T, Sefton BM. 1980. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sci U S A 77:1311-1315. http://dx.doi.org/10.1073/pnas.77.3.1311.
3. Reimand J, Wagih O, Bader GD. 2013. The mutational landscape of phosphorylation signaling in cancer. Sci Rep 3:2651.
4. Skaug B, Chen ZJ. 2010. Emerging role of ISG15 in antiviral immunity. Cell 143:187-190. http://dx.doi.org/10.1016/j.cell.2010.09.033.
5. Levy DE, Marie IJ, Durbin JE. 2011. Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol 1:476-486. http://dx.doi.org/10.1016/j.coviro.2011.11.001.
6. Wimmer P, Schreiner S, Dobner T. 2012. Human pathogens and the host cell SUMOylation system. J Virol 86:642-654. http://dx.doi.org/10.1128/JVI.06227-11.
7. Everett RD, Boutell C, Hale BG. 2013. Interplay between viruses and host sumoylation pathways. Nat Rev Microbiol 11:400-411. http://dx.doi.org/10.1038/nrmicro3015.
8. Rajsbaum R, Garcia-Sastre A. 2013. Viral evasion mechanisms of early antiviral responses involving regulation of ubiquitin pathways. Trends Microbiol 21:421-429. http://dx.doi.org/10.1016/j.tim.2013.06.006.
9. Azuma Y, Tan SH, Cavenagh MM, Ainsztein AM, Saitoh H, Dasso M. 2001. Expression and regulation of the mammalian SUMO-1 E1 enzyme. FASEB J 15:1825-1827.
10. Talamillo A, Sanchez J, Barrio R. 2008. Functional analysis of the SUMOylation pathway in Drosophila. Biochem Soc Trans 36:868-873. http://dx.doi.org/10.1042/BST0360868.
11. Golebiowski F, Matic I, Tatham MH, Cole C, Yin Y, Nakamura A, Cox J, Barton GJ, Mann M, Hay RT. 2009. System-wide changes to SUMO modifications in response to heat shock. Sci Signal 2:ra24.
12. Morris JR. 2010. SUMO in the mammalian response to DNA damage. Biochem Soc Trans 38:92-97. http://dx.doi.org/10.1042/BST0380092.
13. Gareau JR, Lima CD. 2010. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol 11:861-871. http://dx.doi.org/10.1038/nrm3011.
14. Saitoh H, Hinchey J. 2000. Functional heterogeneity of small ubiquitinrelated protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 275: 6252-6258. http://dx.doi.org/10.1074/jbc.275.9.6252.
15. Bernardi R, Pandolfi PP. 2007. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 8:1006-1016. http://dx.doi.org/10.1038/nrm2277.
16. Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T, Yeh ET, Strauss JF, III, Maul GG. 1999. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 147:221-234. http://dx.doi.org/10.1083/jcb.147.2.221.
17. Zhong S, Muller S, Ronchetti S, Freemont PS, Dejean A, Pandolfi PP. 2000. Role of SUMO-1-modified PML in nuclear body formation. Blood 95:2748-2752.
18. Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP. 2006. The mechanisms of PML-nuclear body formation. Mol Cell 24:331-339. http://dx.doi.org/10.1016/j.molcel.2006.09.013.
19. Dundr M, Misteli T. 2010. Biogenesis of nuclear bodies. Cold Spring Harb Perspect Biol 2:a000711.
20. Shuai K, Liu B. 2005. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol 5:593-605. http://dx.doi.org/10.1038/nri1667.
21. Mattoscio D, Segre CV, Chiocca S. 2013. Viral manipulation of cellular protein conjugation pathways: the SUMO lesson. World J Virol 2:79-90. http://dx.doi.org/10.5501/wjv.v2.i2.79.
22. Novoa RR, Calderita G, Arranz R, Fontana J, Granzow H, Risco C. 2005. Virus factories: associations of cell organelles for viral replication and morphogenesis. Biol Cell 97:147-172. http://dx.doi.org/10.1042/BC20040058.
23. Schmid M, Speiseder T, Dobner T, Gonzalez RA. 2014. DNA virus replication compartments. J Virol 88:1404-1420. http://dx.doi.org/10.1128/JVI.02046-13.
24. Hoeben RC, Uil TG. 2013. Adenovirus DNA replication. Cold Spring Harb Perspect Biol 5:a013003.
25. Boyer GS, Leuchtenberger C, Ginsberg HS. 1957. Cytological and cytochemical studies of HeLa cells infected with adeno-viruses. J Exp Med 105:195-216. http://dx.doi.org/10.1084/jem.105.3.195.
26. Stracker TH, Carson CT, Weitzman MD. 2002. Adenovirus oncoproteins inactivate the Mre11-Rad50-NBS1 DNA repair complex. Nature 418:348-352. http://dx.doi.org/10.1038/nature00863.
27. Soria C, Estermann FE, Espantman KC, O'Shea CC. 2010. Heterochromatin silencing of p53 target genes by a small viral protein. Nature 466: 1076-1081. http://dx.doi.org/10.1038/nature09307.
28. Querido E, Blanchette P, Yan Q, Kamura T, Morrison M, Boivin D, Kaelin WG, Conaway RC, Conaway JW, Branton PE. 2001. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev 15:3104-3117. http://dx.doi.org/10.1101/gad.926401.
29. Harada JN, Shevchenko A, Shevchenko A, Pallas DC, Berk AJ. 2002. Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to ubiquitination machinery. J Virol 76:9194-9206. http://dx.doi.org/10.1128/JVI.76.18.9194-9206.2002.
30. Muller S, Dobner T. 2008. The adenovirus E1B-55K oncoprotein induces SUMO modification of p53. Cell Cycle 7:754-758. http://dx.doi.org/10.4161/cc.7.6.5495.
31. Pennella MA, Liu Y, Woo JL, Kim CA, Berk AJ. 2010. Adenovirus E1B 55-kilodalton protein is a p53-SUMO1 E3 ligase that represses p53 and stimulates its nuclear export through interactions with promyelocytic leukemia nuclear bodies. J Virol 84:12210-12225. http://dx.doi.org/10.1128/JVI.01442-10.
32. Wimmer P, Blanchette P, Schreiner S, Ching W, Groitl P, Berscheminski J, Branton PE, Will H, Dobner T. 2013. Cross-talk between phosphorylation and SUMOylation regulates transforming activities of an adenoviral oncoprotein. Oncogene 32:1626-1637. http://dx.doi.org/10.1038/onc.2012.187.
33. Doucas V, Ishov AM, Romo A, Juguilon H, Weitzman MD, Evans RM, Maul GG. 1996. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev 10:196-207. http://dx.doi.org/10.1101/gad.10.2.196.
34. Yondola MA, Hearing P. 2007. The adenovirus E4 ORF3 protein binds and reorganizes the TRIM family member transcriptional intermediary factor 1 alpha. J Virol 81:4264-4271. http://dx.doi.org/10.1128/JVI.02629-06.
35. Forrester NA, Patel RN, Speiseder T, Groitl P, Sedgwick GG, Shimwell NJ, Seed RI, Catnaigh PO, McCabe CJ, Stewart GS, Dobner T, Grand RJ, Martin A, Turnell AS. 2012. Adenovirus E4orf3 targets transcriptional intermediary factor 1gamma for proteasome-dependent degradation during infection. J Virol 86:3167-3179. http://dx.doi.org/10.1128/JVI.06583-11.
36. Sohn SY, Hearing P. 2012. Adenovirus regulates sumoylation of Mre11-Rad50-Nbs1 components through a paralog-specific mechanism. J Virol 86:9656-9665. http://dx.doi.org/10.1128/JVI.01273-12.
37. Sohn SY, Bridges RG, Hearing P. 2014. Proteomic analysis of ubiquitinlike post-translational modifications induced by the adenovirus E4-ORF3 protein. J Virol 89:1744-1755. http://dx.doi.org/10.1128/JVI.02892-14.
38. Ou HD, Kwiatkowski W, Deerinck TJ, Noske A, Blain KY, Land HS, Soria C, Powers CJ, May AP, Shu X, Tsien RY, Fitzpatrick JA, Long JA, Ellisman MH, Choe S, O'Shea CC. 2012. A structural basis for the assembly and functions of a viral polymer that inactivates multiple tumor suppressors. Cell 151:304-319. http://dx.doi.org/10.1016/j.cell.2012.08.035.
39. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, Ginzinger D, McCormick F. 2004. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6:611-623. http://dx.doi.org/10.1016/j.ccr.2004.11.012.
40. O'Shea CC, Soria C, Bagus B, McCormick F. 2005. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 8:61-74. http://dx.doi.org/10.1016/j.ccr.2005.06.009.
41. Manders EMM, Verbeek FJ, Aten JA. 1993. Measurement of colocalization of objects in dual-colour confocal images. J Microscopy 169: 375-382. http://dx.doi.org/10.1111/j.1365-2818.1993.tb03313.x.
42. Castoralova M, Ruml T, Knejzlik Z. 2012. Using dot blot with immunochemical detection to evaluate global changes in SUMO-2/3 conjugation. Biotechniques 2012:1-4. http://dx.doi.org/10.2144/000113925.
43. Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M, Hermiston T, Giedlin M, McCormick F, Fattaey A. 2002. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 1:325-337. http://dx.doi.org/10.1016/S1535-6108(02)00060-0.
44. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔC(T) method. Methods 25: 402-408. http://dx.doi.org/10.1006/meth.2001.1262.
45. Shah GA, O'Shea CC. Viral and cellular genomes activate distinct DNA damage responses. Cell 162:987-1002. http://dx.doi.org/10.1016/j.cell.2015.07.058.
46. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, Reaper PM, Jackson SP, Curtin NJ, Smith GC. 2004. Identification and characterization of a novel and specific inhibitor of the ataxiatelangiectasia mutated kinase ATM. Cancer Res 64:9152-9159. http://dx.doi.org/10.1158/0008-5472.CAN-04-2727.
47. Shepard RN, Ornelles DA. 2004. Diverse roles for E4orf3 at late times of infection revealed in an E1B 55-kilodalton protein mutant background. J Virol 78:9924-9935. http://dx.doi.org/10.1128/JVI.78.18.9924-9935.2004.
48. Lakdawala SS, Schwartz RA, Ferenchak K, Carson CT, McSharry BP, Wilkinson GW, Weitzman MD. 2008. Differential requirements of the C terminus of Nbs1 in suppressing adenovirus DNA replication and promoting concatemer formation. J Virol 82:8362-8372. http://dx.doi.org/10.1128/JVI.00900-08.
49. Gautam D, Bridge E. 2013. The kinase activity of ataxia-telangiectasia mutated interferes with adenovirus E4 mutant DNA replication. J Virol 87:8687-8696. http://dx.doi.org/10.1128/JVI.00376-13.
50. Watts FZ. 2013. Starting and stopping SUMOylation. What regulates the regulator? Chromosoma 122:451-463.
51. Sang J, Yang K, Sun Y, Han Y, Cang H, Chen Y, Shi G, Wang K, Zhou J, Wang X, Yi J. 2011. SUMO2 and SUMO3 transcription is differentially regulated by oxidative stress in an Sp1-dependent manner. Biochem J 435:489-498. http://dx.doi.org/10.1042/BJ20101474.
52. Boggio R, Colombo R, Hay RT, Draetta GF, Chiocca S. 2004. A mechanism for inhibiting the SUMO pathway. Mol Cell 16:549-561. http://dx.doi.org/10.1016/j.molcel.2004.11.007.
53. Jentsch S, Psakhye I. 2013. Control of nuclear activities by substrateselective and protein-group SUMOylation. Annu Rev Genet 47:167-186. http://dx.doi.org/10.1146/annurev-genet-111212-133453.
54. Schmidt D, Muller S. 2003. PIAS/SUMO: new partners in transcriptional regulation. Cell Mol Life Sci 60:2561-2574. http://dx.doi.org/10.1007/s00018-003-3129-1.
55. Evans JD, Hearing P. 2003. Distinct roles of the adenovirus E4 ORF3 protein in viral DNA replication and inhibition of genome concatenation. J Virol 77:5295-5304. http://dx.doi.org/10.1128/JVI.77.9.5295-5304.2003.
56. Hoppe A, Beech SJ, Dimmock J, Leppard KN. 2006. Interaction of the adenovirus type 5 E4 Orf3 protein with promyelocytic leukemia protein isoform II is required for ND10 disruption. J Virol 80:3042-3049. http://dx.doi.org/10.1128/JVI.80.6.3042-3049.2006.
57. Stracker TH, Lee DV, Carson CT, Araujo FD, Ornelles DA, Weitzman MD. 2005. Serotype-specific reorganization of the Mre11 complex by adenoviral E4orf3 proteins. J Virol 79:6664-6673. http://dx.doi.org/10.1128/JVI.79.11.6664-6673.2005.
58. Forrester NA, Sedgwick GG, Thomas A, Blackford AN, Speiseder T, Dobner T, Byrd PJ, Stewart GS, Turnell AS, Grand RJ. 2011. Serotype-specific inactivation of the cellular DNA damage response during adenovirus infection. J Virol 85:2201-2211. http://dx.doi.org/10.1128/JVI.01748-10.
59. Ullman AJ, Reich NC, Hearing P. 2007. Adenovirus E4 ORF3 protein inhibits the interferon-mediated antiviral response. J Virol 81:4744-4752. http://dx.doi.org/10.1128/JVI.02385-06.
60. Ullman AJ, Hearing P. 2008. Cellular proteins PML and Daxx mediate an innate antiviral defense antagonized by the adenovirus E4 ORF3 protein. J Virol 82:7325-7335. http://dx.doi.org/10.1128/JVI.00723-08.
61. Chahal JS, Qi J, Flint SJ. 2012. The human adenovirus type 5 E1B 55 kDa protein obstructs inhibition of viral replication by type I interferon in normal human cells. PLoS Pathog 8:e1002853. http://dx.doi.org/10.1371/journal.ppat.1002853.
62. Pombo A, Ferreira J, Bridge E, Carmo-Fonseca M. 1994. Adenovirus replication and transcription sites are spatially separated in the nucleus of infected cells. EMBO J 13:5075-5085.
63. Nordqvist K, Ohman K, Akusjarvi G. 1994. Human adenovirus encodes two proteins which have opposite effects on accumulation of alternatively spliced mRNAs. Mol Cell Biol 14:437-445.
64. Gill G. 2003. Post-translational modification by the small ubiquitin-related modifier SUMO has big effects on transcription factor activity. Curr Opin Genet Dev 13:108-113. http://dx.doi.org/10.1016/S0959-437X(03)00021-2.
65. Rytinki MM, Kaikkonen S, Pehkonen P, Jaaskelainen T, Palvimo JJ. 2009. PIAS proteins: pleiotropic interactors associated with SUMO. Cell Mol Life Sci 66:3029-3041. http://dx.doi.org/10.1007/s00018-009-0061-z.